Safety and Efficacy of a Novel Radiofrequency Device for Submucosal Turbinate Reduction - A Prospective, Open-Label Pilot Trial.
Ann Otol Rhinol LaryngolMay 23, 2026 (epub)
Clinical ResearchOtolaryngology (ENT)
Amani Daoud, Shiri Geva, Erez Hassidov et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective, single-arm pilot trial evaluated the safety and efficacy of a novel submucosal fractional radiofrequency treatment for inferior turbinate hypertrophy in 22 patients. The study found significant improvements in nasal obstruction, with NOSE scores decreasing from 71.2 to 30.0 at 1 month (P < .001) and sustained improvement at 3 months.
Key findings
- NOSE score improved from 71.2 to 30.0 at 1 month (P < .001).
- VAS scores for nasal obstruction decreased from 7.4 to 3.2 at 1 month (P < .0001).
- Endoscopic grading showed turbinate size reduction at both follow-up points (P < .05).
- Average VAS score for pain was 3.4, indicating good tolerability.
Why it matters
The findings suggest that submucosal fractional radiofrequency treatment is a safe and effective option for patients with inferior turbinate hypertrophy, potentially reducing the need for more invasive surgical interventions.